| 查看: 1466 | 回复: 8 | |||
| 本帖产生 1 个 翻译EPI ，点击这里进行查看 | |||
| 当前只显示满足指定条件的回帖，点击这里查看本话题的所有回帖 | |||
[交流]
一句话求助高人！急啊!（关于临床方面的，英译汉）
|
|||
| The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients。Sample Text |
回复此楼» 猜你喜欢
博士读完未来一定会好吗
已经有6人回复
-
小论文投稿
已经有3人回复
-
Bioresource Technology期刊，第一次返修的时候被退回好几次了
已经有9人回复
-
心脉受损
已经有3人回复
-
到新单位后，换了新的研究方向，没有团队，持续积累2区以上论文，能申请到面上吗
已经有8人回复
-
申请2026年博士
已经有6人回复
-
请问哪里可以有青B申请的本子可以借鉴一下。
已经有5人回复
| TYGACIL was evaluated in adults for the treatment of complicated skin and skin structure infections (cSSSI) in two randomized, double-blind, active-controlled, multinational, multicenter studies (Studies 300 and 305). These studies compared TYGACIL (100 mg intravenous initial dose followed by 50 mg every 12 hours) with vancomycin (1 g intravenous every 12 hours)/aztreonam (2 g intravenous every 12 hours) for 5 to 14 days. Patients with complicated deep soft tissue infections including wound infections and cellulitis (≥10 cm, requiring surgery/drainage or with complicated underlying disease), major abscesses, infected ulcers, and burns were enrolled in the studies. The primary efficacy endpoint was the clinical response at the test of cure (TOC) visit in the co-primary populations of the clinically evaluable (CE) and clinical modified intent-to-treat (c-mITT) patients. See Table 6. Clinical cure rates at TOC by pathogen in the microbiologically evaluable patients are presented in Table 7. |
7楼2010-11-03 15:24:17
petrocatal
木虫 (正式写手)
- 翻译EPI: 134
- 应助: 23 (小学生)
- 贵宾: 0.01
- 金币: 3436.6
- 红花: 1
- 帖子: 959
- 在线: 299.5小时
- 虫号: 557856
- 注册: 2008-05-13
- 性别: GG
- 专业: 有机化工
2楼2010-11-03 13:09:58
3楼2010-11-03 13:58:57
4楼2010-11-03 13:59:43